Clinical Research Directory
Browse clinical research sites, groups, and studies.
PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
Sponsor: Stony Brook University
Summary
In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.
Official title: Central Cholinergic Dysfunction in Depression: PET Imaging of a Novel Treatment Target With [18F]VAT to Assess the Antidepressant Effect of Nicotine
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
14
Start Date
2024-10-03
Completion Date
2029-09-30
Last Updated
2025-07-31
Healthy Volunteers
Yes
Conditions
Interventions
Nicotine transdermal patch
The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).
PET Scan with [18F] VAT
All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.
Locations (1)
Stony Brook University: Dept of Psychiatry
Stony Brook, New York, United States